I agree with everything you say. On the face of it, all Acadia...

I agree with everything you say. On the face of it, all Acadia has to do is to begin development of Trofinetide for any indication other than the big 4, and Neuren is prevented from doing the same. While the prospect of them doing so may be largely hypothetical, as you point out there is potential for serious commercial disruption. Say Neuren realised that 2591 was likely to be able to cure autism and Alzheimer's, and was halfway through stage 3 trials with 2591 for those indications, and Acadia suddenly decided to "develop" Trofinetide for the same things. Would that prevent Neuren from going any further? Might there be a prospect of Acadia agreeing to drop the "development" in exchange for a healthy payout? These people are Americans, with the commercial morals of Fagin.
The press release was very short on detail on this point. Perhaps we are owed some clarification.